Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Chase Investment Counsel Corp Has $570,000 Stake in Gilead Sciences, Inc. $GILD
04:50am, Tuesday, 24'th Feb 2026
Chase Investment Counsel Corp trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 50.1% in the third quarter, according to the company in its most recent Form 13F filing with the
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
Gilead Sciences to Present at Upcoming Investor Conferences
04:05pm, Monday, 23'rd Feb 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Ca
Gilead Sciences Expands Oncology Portfolio with Arcellx Acquisition
12:14pm, Monday, 23'rd Feb 2026
Gilead Sciences (GILD) is set to enhance its oncology and cell therapy capabilities by acquiring Arcellx (ACLX). This acquisition deepens their existing collabo
Gilead pays $7.8bn to take full control of promising multiple myeloma therapy
08:20am, Monday, 23'rd Feb 2026
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology company at $7.8 billion, converting an existing partnership into outright own
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
07:52am, Monday, 23'rd Feb 2026
Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the biopharma company said on Monday, as it looks to strengthen its lineup of cancer tr
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout
07:13am, Monday, 23'rd Feb 2026
Shares of Arcellx shot up toward a fresh record in early Monday trading, after Gilead Sciences agreed to buy the rest of the shares it doesn't already own of the biotechnology company, in a deal with
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
06:36am, Monday, 23'rd Feb 2026
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.
This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.
06:34am, Monday, 23'rd Feb 2026
Gilead Sciences is paying an 80% premium to Friday's closing price.
Gilead to acquire Arcellx for $7.8 billion
06:08am, Monday, 23'rd Feb 2026
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
06:01am, Monday, 23'rd Feb 2026
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: AC
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
06:01am, Monday, 23'rd Feb 2026
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Purchases 26,882 Shares of Gilead Sciences, Inc. $GILD
05:14am, Saturday, 21'st Feb 2026
Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 52.1% in the third quarter, according to the company in its most r
Time To Take Profits On Gilead Sciences (Rating Downgrade)
02:24pm, Friday, 20'th Feb 2026
Gilead Sciences, Inc. shares have risen more than 43% over the past year. I continue to believe that its three key drugs remain Biktarvy, Yeztugo, and Livdelzi, whose total sales grew 10.8% year-over-
China Universal Asset Management Co. Ltd. Increases Holdings in Gilead Sciences, Inc. $GILD
07:08am, Friday, 20'th Feb 2026
China Universal Asset Management Co. Ltd. boosted its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 4.3% in the undefined quarter, according to the company in its most recent Form 13F filing wit
